Authors
Stuti Shah, Hesham Sheashaa, Elizabeth Brahier, Nicholas G Smedira, Susan K Keen, Milind Y Desai
Published in
Expert review of cardiovascular therapy. Nov 15, 2026. Epub Nov 15, 2026.
Abstract
Obstructive hypertrophic cardiomyopathy is characterized by dynamic left ventricular outflow tract obstruction that can cause substantial symptoms and morbidity. The expanding range of pharmacologic, surgical, and transcatheter options has made treatment selection increasingly complex.
This narrative review examines conventional medical therapy, cardiac myosin inhibitors, surgical septal myectomy, alcohol septal ablation, and emerging investigational septal reduction strategies. It also discusses patient selection, procedural risks, multimodality imaging, and the importance of experienced hypertrophic cardiomyopathy centers. A targeted narrative search of English-language literature indexed in PubMed was conducted from April through 31 July 2026, considering clinical trials, observational studies, guidelines, and relevant reviews.
Cardiac myosin inhibitors are likely to modify the timing of septal reduction therapy rather than replace it. Future progress will depend on mechanism-based treatment selection, appropriate early referral, rigorous validation of emerging procedures, and integration of advanced imaging and multidisciplinary expertise to match each patient with the most suitable therapy.
PMID:
43035341
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0